• Home >>
  • Pharmaceuticals and Healthcare >>
  • Intravenous (IV) Iron Drugs Market - Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis and Competitive Analysis 2017 - 2025

Intravenous (IV) Iron Drugs Market - Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis and Competitive Analysis 2017 - 2025

ID: 46960 January, 2018 Region : Global Pages Reports Monitor

Global Intravenous (IV) Iron Drugs Market by Product Type (Ferric Carboxyl Maltose, Iron Sucrose, Iron Dextran, Ferric Gluconate), by Therapeutic Application (nephrology, cardiology, gynaecology, oncology, , surgeries)-Global Forecast till 2025
Market overview

Human body requires sufficient amount of nutrients in the form of vitamin and minerals to perform its functions normally. Iron is one of the imperative mineral. Iron being major part of haemoglobin serves the important function by carrying oxygen to each and every part of body via blood. That carried oxygen is then further employed by the cells and tissue to produce energy required to perform all vital biological process. Deficiency of iron in the body can cause severe condition like Anaemia. Intravenous medication is the fastest route of administration ensuring 100% bioavailability. The segment of non-dextran intravenous iron drugs is gaining increasingly more attention over conventional dextran intravenous iron drugs. The capacity of aforementioned segment to carry large dosages of intravenous iron drugs as compared to later is empowering the demand for non-dextran intravenous iron drugs.


Global Market of Intravenous drugs is estimated to have lucrative growth owing to increased awareness in personal care and healthcare, advancement in the technology of IV Iron drugs, high number of dialysis patient,  development in intravenous iron drug which help in retaining iron stores boost the market growth. Moreover rising incidences of iron deficiency with dissatisfied need, upsurge in healthcare expenditure and increased prevalence of diseases resulting into iron insufficiency is boosting the market for future growth. In addition to that gynaecology section is the prime factor under therapeutic application driving the market considering iron deficiency anaemia more prominent in woman owing to excessive bleeding during childbirth and heavy menstruation. Nevertheless, side-effects associated with the IV drugs and rigorous government guidelines retard the growth of the market. Developing countries are showcasing their interests in the advanced intravenous drug development which serves as opportunity for new market players to enter the market. 


Segmentation
The global market of IV drugs in segmented considering various product types, based on product type it is divided into four sections Ferric carboxyl maltose, iron sucrose, iron dextran, and ferric gluconate. Furthermore on the basis of therapeutic application it is classified into nephrology, cardiology, gynaecology, oncology, gastroenterology, surgeries and chronic heart failures.


Regional Analysis
Under regional analysis of intravenous drug market divides it into North America, Europe, Asia-Pacific and LAMEA.  North America Accounts for major share followed by Europe and Asia-Pacific. US represents the highest market for IV iron drugs in North America whereas in Europe U.K, France, Germany holds the major market share. The growing prevalence of iron deficiency anaemia and the existence of few of the global market’s leading player in the region imputes to the high future growth prospects of North America intravenous iron drugs market. Asia-Pacific is anticipated to propel the market in near future owing to increased aged population, high prevalence of kidney disorders and unfulfilled requirement of iron. Furthermore, slowing developing healthcare sector and rising awareness among end-users are anticipated to boost the demand for the intravenous iron drugs in Latin America, the Middle East & Africa.  


Key Players
Major operating players in the market include Galenica, AMAG Pharmaceuticals, Inc., PHARMACOSMOS A/S, Allergan PLC, Daichi Sankyo Company Ltd., Nippon Shinyaku Co. Ltd., Sanofi, Rockwell Medical Technologies, Inc., Fresenius Medical Care AG & Co. and Luitpold Pharmaceuticals, Inc.,


Global Intravenous Iron Drugs Market segmentation
• By product type
o Ferric carboxyl maltose
o Iron sucrose
o Iron dextran
o Ferric gluconate


• By Therapeutic application
o Nephrology
o Cardiology
o Gynecology
o Oncolohy
o Gastroenterology
o Surgeries & Chronic heart failures


• By Geography
o North America
 U.S
 Canada
 Mexico
o Europe
 UK
 Germany
 France
 Rest of Europe
o Asia-Pacific
 China
 India
 Japan
 Rest of APAC
o LAMEA
 Brazil
 South Africa
 Rest of LAMEA


• Market Key Players
o Galenica
o AMAG Pharmaceuticals, Inc.
o PHARMACOSMOS A/S
o Allergan PLC
o Daichi Sankyo Company Ltd.
o Nippon Shinyaku Co. Ltd.
o Sanofi
o Rockwell Medical Technologies, Inc.
o Fresenius Medical Care AG & Co.
o Luitpold Pharmaceuticals, Inc.,

Research Scope
The study for Global Intravenous Drugs Market will provide market size, estimates and forecast based on the following years: 
 
Historic data: 2015  Base Year Estimate: 2016  Forecast: 2017 to 2025


The report has been categorized in two distinctive sections, where the first category titled as Market Overview provides a holistic view of the market, key trends, drivers, challenges/restraints or opportunities with their current and expected impact on the overall industry sales. 
Our analyst implement several qualitative tools such as Ansoff’s Matrix, PESTEL analysis, Porter’s five force analysis among other to interpret and represent key industry findings. 
The second section of the study provides market size, estimates and forecast for key market segments and regional market. The final part of the report highlights key manufacturers/vendors operating in the associated market. 


1. Introduction
1.1. Market Definition
1.2. Market Scope


2. Research Methodology
2.1. Primary Research
2.2. Secondary Sources
2.3. Assumptions & Exclusions


3. Market Overview
3.1. Research Report Segmentation & Scope
3.2. Key Market Trend Analysis
3.2.1. Market Drivers
3.2.2. Market Restraint/Challenges
3.2.3. Market Opportunities
3.3. Porter’s Five Forces Analysis
3.4. Potential Venture Avenues
3.5. Market Share Analysis, 2016 


4. Product Type Overview
4.1. Introduction
4.2. Market Size & Forecast, 2015 to 2025
4.2.1. Ferric carboxyl maltose
4.2.2. Iron sucrose
4.2.3. Iron dextran
4.2.4. Ferric gluconate
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


5. Therapeutic Application Overview
5.1. Introduction
5.2. Market Size & Forecast, 2015 to 2025
5.2.1. Nephrology
5.2.2. Cardiology
5.2.3. Gynecology
5.2.4. Oncolohy
5.2.5. Gastroenterology
5.2.6. Surgeries & Chronic heart failures
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


6. Regional Overview
6.1. Introduction
6.2. Market Size & Forecast, 2015 to 2025
6.2.1. North America
6.2.1.1. U.S.
6.2.1.2. Canada
6.2.1.3. Mexico
6.2.2. Europe
6.2.2.1. UK
6.2.2.2. Germany
6.2.2.3. France
6.2.2.4. Italy 
6.2.2.5. Spain
6.2.2.6. Turkey
6.2.2.7. Rest of Europe
6.2.3. Asia-Pacific
6.2.3.1. China
6.2.3.2. India
6.2.3.3. Japan
6.2.3.4. South Korea
6.2.3.5. Rest of Asia-Pacific
6.2.4. LAMEA
6.2.4.1. Brazil
6.2.4.2. Saudi Arabia
6.2.4.3. South Africa
6.2.4.4. Rest of LAMEA
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


7. Manufacturer/ Vendor Profile
7.1. The following attributes will be considered while profiling key manufacturers in this industry: 
7.1.1. Company Overview
7.1.2. Financial Synopsis
7.1.3. Recent Developments
7.1.4. R&D Investments (if any)
7.1.5. Strategy Overview (Analyst Perspective)
7.1.6. Product Portfolio
7.2. Companies Profiled
7.2.1. Galenica
7.2.2. AMAG Pharmaceuticals, Inc.
7.2.3. PHARMACOSMOS A/S
7.2.4. Allergan PLC
7.2.5. Daichi Sankyo Company Ltd.
7.2.6. Nippon Shinyaku Co. Ltd.
7.2.7. Sanofi
7.2.8. Rockwell Medical Technologies, Inc.
7.2.9. Fresenius Medical Care AG & Co.
7.2.10. Luitpold Pharmaceuticals, Inc.,
 (Note: The companies mentioned above are tentative in nature, and profiles of other market players not listed here can be included on request.)

Request Sample

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Request Discount

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Related Reports




Get 15 minutes of free Consultation When you request a Sample Report!

24/7 Research Report

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone:

+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected]